Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clazakizumab - CSL Behring

Next Previous
Drug Profile

Clazakizumab - CSL Behring

Alternative Names: ALD-518; Anti-IL-6 mAb - CSL Behring; BMS-945429; CSL 300; LY-5724886

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alder Biopharmaceuticals
  • Developer CSL Behring; ICON; Lundbeck Seattle BioPharmaceuticals Inc.; Vitaeris
  • Class Anti-inflammatories; Antianaemics; Antipsoriatics; Antirheumatics; Antivirals; Monoclonal antibodies; Urologics
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal transplant rejection
  • Phase II/III Renal failure
  • Phase II COVID 2019 infections; Inflammation
  • Suspended Anaemia; Cachexia; Fatigue; Stomatitis
  • Discontinued Crohn's disease; Graft-versus-host disease; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 25 Aug 2026 Eli Lilly and Co plans the phase II CLARITY-CRP trial for Cardiovascular disorders, Type 2 Diabetes mellitus and kidney failure in USA, Argentina, Japan and Puerto Rico (SC) (NCT07783802)
  • 17 Jun 2026 Phase-I clinical trials in Renal failure in China (IV) (NCT07619820)
  • 02 Jun 2026 CSL Behring plans a phase Ib pharmacokinetics trial for Renal failure in China (IV, Injection) in June 2026 (NCT07619820)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top